Dejka Araujo, MD MD Anderson Cancer Center, Houston, TX A PHASE II TRIAL OF PERIFOSINE IN PATIENTS WITH CHEMO-INSENSITIVE SARCOMAS A SARCOMA ALLIANCE FOR RESEARCH THROUGH COLLABORATION (SARC) STUDY Study Update – November 2007 Dejka Araujo, MD MD Anderson Cancer Center, Houston, TX

Patients with < 2 forms of prior chemotherapy stratified by Extra-Skeletal Myxoid Chondrosarcoma Conventional Chondrosarcoma Alveolar Soft Part Sarcoma Perifosine 100 mg po qhs daily Evaluate q 12 weeks SD, PR or CR Progression Continue On Study Remove From Study

Objectives Primary Secondary Evaluate the response rate defined by both Choi and RECIST criteria of single agent perifosine Secondary Evaluate Time to Progression Evaluate the Clinical Benefit Rate (SD of 6 mo’s or greater)

Major Inclusion / Exclusion Measurable Disease Documented progression by Choi Criteria Age > 13 years Exclusion > 2 prior cytotoxic regimens for metastatic disease (unless exempted)

Participants (12) / Enrollment (59) Extra-Skeletal Myxoid Chondrosarcoma - 15 Conventional Chondrosarcoma - 33 Alveolar Soft Part Sarcoma - 11 MD Anderson – 13 Dejka Araujo, MD Penn – 12 Arthur Staddon, MD Sarcoma Oncology – 11 Sant Chawla, MD MSKCC - 8 Robert Maki, MD Michigan - 5 Scott Schuetze, MD Mass General – 5 Edwin Choy, MD Fox Chase – 2 Margaret von Mehren, MD Washington Cancer – 2 Dennis Priebat, MD OHSU – 1 Christopher Ryan, MD Others Open: DFCI, Moffitt, UFL